Analysis of IL-2 receptor expression and of the biological effects of IL-2 gene transfection in small-cell lung cancer

British Journal of Cancer

Volumn 74, Issue 5, 1996, Pages 788-795

  Meazza, R ^a,b   Marciano, S ^a   Sforzini, S ^a   Orengo, A M ^a   Coppolecchia, M ^a   Musiani, P ^c   Ardizzoni, A ^a   Santi, L ^a,b   Azzarone, B ^d   Ferrini, S ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d HÔPITAL PAUL BROUSSE   (France)

Author keywords

Interleukin 2; Interleukin 2 receptor; Lung cancer; Transfection; Xenotransplant

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA;

ARTICLE; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUNG SMALL CELL CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 9544258381     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.437     Document Type: Article

References (37)

1. ABDEL-WAHAB Z, LI WP, OSANTO S, DARROW TL, HESSLING J, VERVAERT CE, BURRASCANO M, BARBER J AND SEIGLER HF. (1994). Transduction of human melanoma cells with interleukin-2 gene reduces tumorigenicity and enhances host antitumour immunity: a nude mouse model. Cell. Immunol., 159, 26 39.
2. ALLIONE A, CONSALVO M, NANNI P, LOLLINI PL, CAVALLO F, GIOVARELLI M, FORNI M, GULINO A, COLOMBO MP, DELLABONA P, HOCK KH, BLANKSTEIN T, ROSENTHAL FM, GANSBACHER B, BOSCO MC, MUSSO T, GUSELLA L AND FORNI G. (1994). Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis α, granulocyte-macrophage colony-stimulating factor, and γ-interferon gene or admixed with conventional adjuvants. Cancer Res., 54, 6022 6026.
3. BLANKESTEIN T, QIN Z, UBERLA K, MULLER W, ROSEN H, VOLK HD AND DIAMANTSTEIN T. (1991). Tumor suppression after tumor cell-targeted tumor necrosis factor a gene transfer. J. Exp. Med., 173, 1047-1052.
4. CASSILETH PA. (1995). Phase I study of transfected cancer cells expressing the IL-2 gene product in limited stage SCLC. Hum. Gene Ther., 6, 369 383.
5. CAVALLO F, GIOVARELLI M, GULINO A, VACCA A, STOPPACCIARO A, MODESTI A AND KORNI G. (1992). Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to non-immunogenic murine mammary adenocarcinoma made immunogenic by IL2 gene. J. Immunol., 149, 3627-3635.
6. CLAMON G, HERNDON J, PERRY MC, OZER H, KREISMAN H, MAHER T, ELLERTON J AND GREEN MR. (1993). Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of cancer and leukemia group B. J. Natl Cancer Inst., 85, 316-320.
7. COLOMBO MP AND KORNI G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today, 15, 48-51.
8. COLOMBO MP, MODESTI A, PARMIANI G AND FORNI G. (1992). Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocytc cross-talk. Cancer Res., 52, 4853-4857.
9. DE LEIJ L, POSTMUS PE, BUYS CHCM, ELEMA JD, RAMAERKS F, POPPEMA S, BROUWER M, VAN DER VEEN AY, MESANDER G AND THE TH. (1985). Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. Cancer Res., 45, 6024 6033.
10. DOYLE A, MARTIN WJ, FUNA K, GAZDAR A, CARNEY D, MARTIN SE, LINNOILA I, CUTTITTA F, MULSHINE J, BUNN P AND MINNA J. (1985). Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J. Exp. Med., 161, 1135 1151.
11. FEARON ER, PARDOLL DM, ITAYA T, GOLUMBEK P, LEVITSKY HI, SIMONS JW, KARASUYAMA H, VOGELSTEIN B AND FROST P. (1990). Interleukin-2 production bypasses T helper function in the generation of an antitumour response. Cell, 60, 397 403.
12. FERRINI S, MIESSCHER S, ZOCCHI MR, VON FLIEDNER V AND MORETTA A. (1987). Phenotypic and functional characterization of recombinant interleukin-2 (rIL-2)-induced activated killer cells: analysis at the population and clonal levels. J. Immunol., 138, 1297-1302.
13. FRAZIER-SCOTT K, HATZAKIS H, SEONG D, JONES CM AND WU KK. (1988). Influence of natural and recombinant interleukin-2 on endothelial cell arachidonate metabolism. J. Clin. Invest., 82, 1877-1883.
14. GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNFRJI R AND GILBOA E. (1990). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172, 1217 1224.
15. HICKS C, COOLEY MA AND PENNY R. (1991). Investigation of interleukin-2 receptors on human endothelial cells, Growth Factors, 5, 201-208.
16. GAUGLER B, VAN DEN N EYNDE B, ROMERO P, GAFORIO JJ, IMPLAEN E, LETHE B, BRASSEUR F AND BOON T. (1994). Human MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med., 179, 921 930.
17. HARA I, NGUYEN H, TAKECHI Y, GANSBACHER B, CHAPMAN PB AND HOUGHTON AN. (1995). Rejection of mouse melanoma elicited by local secretion of interleukin 2: implicating macrophages without T cells or natural killer cell in tumor rejection. Int. J. Cancer, 61, 253-260.
18. IHDE DC. (1995). Current perspectives in the treatment of small cell lung cancer: educational symposium of the VII World Congress on Lung Cancer. Lung Cancer, 12, (suppl. 3), 1-3.
19. LONG EO, ROSEN-BRONSON S, KARP DR, SEKALY RP AND JARAQUEMADA D. (1991). Efficient cDNA expression vectors for stable and transient expression of HLA-DR in tranfected fibroblast and lymphoid cells. Hum. Immunol., 31, 229 235.
20. MCMILLAN DN, KERNOHAN NM, FLETT ME, HEYS SD, DEEHAN DJ, SEWELL HF, WALKER F AND EREMIN O. (1995). Interleukin 2 receptor expression and interleukin 2 localization in human solid tumour cells in vitro and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int. J. Cancer, 60, 766-772.
21. MANTOVANI A, BUSSOLINO F AND DEJANA E. (1992). Cytokine regulation of endothelial cell function. FASEB J., 6, 2591 2599.
22. MING WJ, BERSANI L AND MATOVANI A. (1987). Tumor necrosis factor is chemotactic factor for monocytes and polymorphonuclear leukocytes. J. Immunol., 138, 1469 1474.
23. PLAISANCE S, RUBINSTEIN E, ALILECHE A, HAN DS, SAHRAOUI Y, MINGARI MC, BELLOMO R, RIMOLDI D, COLOMBO MP, JASMIN C, CARREL S AND AZZARONE B (1993). Human melanoma cells express a functional interleukin-2 receptor. Int. J. Cancer, 55, 164-170.
24. RIMOLDI D, SALVI S, HARTMANN F, SCREYER M, BLUM S, ZOGRAFOS L, PLAISANCE S, AZZARONE B AND CARREL S. (1993). Expression of IL-2 receptors in human melanoma cells. Anticancer Res., 13, 555-564.
25. ROSENTHAL FM, CRONIN K, BANNERJI R, GOLDE DW AND GANSBACHER B. (1994). Augmentation of antitumour immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and Interferon-γ cDNAs. Blood, 83, 1289-1298.
26. SATO N AND MIYAJIMA A. (1994). Multimeric cytokme receptors: common versus specific functions. Curr. Opin. Cell. Biol., 6, 174 179.
27. SCHMIDT-WOLF G AND SCHMIDT-WOLF IGH. (1995). Cytokines and clinical gene therapy. Eur. J. Immunol., 25, 1137-1140.
28. SHTIVELMAN E AND NAMIKAWA R. (1995). Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc. Natl Acad. Sci. USA, 92, 4661-4665.
29. TAKESHITA T, GOTO Y, TADA K, NAGATA K, ASAO H AND SUGAMURA K. (1989). Monoclonal antibody defining a molecule possibly identical to the p75 subunit of the interleukin-2 receptor. J. Exp. Med., 169, 1323-1332.
30. TANIGUCHI T AND MINAMI Y. (1993). The IL-2/IL-2 receptor system. A current overview. Cell, 73, 5-8.
31. TRAVERSARI C, VAN DER BRUGGEN P, LEUSCHER IF, LURQUIN C, CHOMEZ P, VAN PEL A, DE PLAFN E, AMAR-COSTESEC A AND BOON T. (1992). A nonapeptide encoded by human gene MAGE-1 is recognised on HLA-I by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med., 176, 1453-1457.
32. URGAN JL, SHEPARD HM, ROSENTHEIN JL, SUGARMAN BJ AND SCHREIBER H. (1986). Tumor necrosis factor: a potent effector molecule for tumor cell killing by active macrophages. Proc. Natl Acad. Sci. USA, 83, 5233-5237.
33. VECCHI A, GARLANDA C, LAMPUGNANI MG, RESNATI M, MATTEUCCI C, STOPPACCIARO A, SCHNURCH H, RISAU W, RUCO L, MANTOVANI A AND DEJANA B. (1994). Monoclonal antibodies specific for endothelial cells of mouse blood vessels. Their application in the identification of adult and embryonic endothelium. Eur. J. Cell. Biol., 63, 247-254.
34. VERSTOVSEK S, MACCUBBIN D, EHRKE MJ AND MIHICH E (1992). Tumoricidal activation of murine resident peritoneal macrophages by interleukin 2 and tumor necrosis α. Cancer Res., 52, 3880-3885.
35. VOSS SD, SONDEL PM AND ROBB RJ. (1992). Characterization of the human interleukin-2 receptor (IL2R) expressed on human natural killer cells activated in vivo by IL2: association of the p64 IL-2Rγ chain with the IL-2R β chain in the functional intermediate affinity IL-2R. J. Exp. Med., 176, 531-541.
36. WEIDMANN E, SACCHI M, PLAISANCE S, HEO DS, YASUMURA S, LIN W, JOHNSON JT, HERBERMAN RB, AZZARONE B AND WHITESIDE T. (1992). Receptors for interleukin 2 on squamous cell carcinoma cell lines and tumor in situ. Cancer Res., 52, 5963 5970.
37. YASUMURA S, LIN W, WEIDMANN E, HEBDA P AND WHITESIDE T. (1994). Expression of interleukin 2 receptors on human carcinoma cell lines and tumor growth inhibition by interleukin 2. Int. J. Cancer, 589, 225-234.